)
Visual22 Oct 2025
Epiroc's cash spent on M&A
AVROBIO (AVRO) investor relations material
AVROBIO Q4 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2024 earnings summary19 Mar, 2025
Executive summary
Transitioned to a public company in 2024 and reported positive interim results from TX45 Phase 1b trial in PH-HFpEF patients, supporting ongoing Phase 2 APEX trial endpoints and population.
Enrolled first subject in TX45 Phase 1b Part B trial for HFrEF in March 2025; topline results expected 2H 2025.
Completed $185M private placement in February 2025, extending cash runway into Q4 2028.
Financial highlights
Cash and cash equivalents were $141.2M as of December 31, 2024, down from $159.1M at September 30, 2024.
Research and development expenses rose to $9.2M in Q4 2024 from $7.1M in Q4 2023, mainly due to increased clinical and manufacturing activities.
General and administrative expenses increased to $4.8M in Q4 2024 from $2.3M in Q4 2023, reflecting higher costs as a public company.
Net loss for Q4 2024 was $12.4M, compared to $7.9M in Q4 2023; full-year net loss was $58.0M versus $42.8M in 2023.
Outlook and guidance
Cash position, including proceeds from the private placement, expected to fund operations through key TX45 Phase 1b/2 readouts and TX2100 clinical development into Q4 2028.
TX45 Phase 1b Part B topline results anticipated in 2H 2025; APEX Phase 2 topline results expected in 2026.
TX2100 Phase 1 trial for HHT planned to initiate in Q4 2025 or Q1 2026, pending completion of IND-enabling studies.
Assess TX45's competitive advantages.
Explain the TX2100 target GPCR rationale.
Detail the use of PIPE financing proceeds.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
AVROBIO, Inc. is a clinical-stage biotechnology company specializing in the development of gene therapies using a lentiviral-based platform. These therapies are designed to treat rare diseases with a single dose, and involve modifying hematopoietic stem cells extracted from patients. AVROBIO focuses on a range of genetic disorders, employing its proprietary plato® platform to optimize these therapies. Notable diseases targeted by AVROBIO's gene therapies include Gaucher disease, Pompe disease, cystinosis, and Hunter syndrome, with several treatments in various stages of clinical trials. The company was established in 2015 and is based in Cambridge, Massachusetts. Its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage